Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ab&B Bio-tech's human diploid cell rabies vaccine is a freeze-dried, inactivated biologic developed for both pre-exposure and post-exposure prophylaxis against rabies. Cultivated using human diploid cells—a substrate known for high safety and low adverse reaction rates compared to animal-derived cell lines—this vaccine is designed to stimulate a robust immune response against the rabies virus. It has entered Phase III clinical trials to evaluate its safety and immunogenicity across various immunization schedules, including the five-dose Essen regimen, the four-dose Zagreb (2-1-1) regimen, and simplified four-dose schedules. The manufacturing process emphasizes high purification and potency, positioning it as a next-generation alternative to traditional Vero cell-based rabies vaccines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rabies vaccine (human diploid cell) (Ab&B Bio-tech).